Video

Dr. Patel on Key Updates from First-Line Trials in NSCLC

Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.

Manish Patel, DO, hematologist, oncologist, associate professor of medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer (NSCLC)

The phase 3 EMPOWER-Lung 3 trial (NCT03409614), studying cemiplimab-rwlc (Libtayo) with chemotherapy, produced positive data similar to the phase 3 KEYNOTE-189 trial (NCT02578680), which evaluated pembrolizumab (Keytruda) plus chemotherapy, Patel explains. Notably, EMPOWER-Lung 3 demonstrated a particular benefit in patients with squamous cell NSCLC, Patel adds.

Additionally, data from the phase 3 POSEIDON trial (NCT03164616) supported the FDA approval of durvalumab (Imfinzi) and tremelimumab-actl (Imjudo) with platinum-based chemotherapy for the treatment of adult patients with metastatic NSCLC without sensitizing EGFR mutations or ALKaberrations, Patel continues. POSEIDON was another example of a trial showing the benefit of treating patients with chemotherapy in combination with a PD-1 inhibitor and CTLA-4 inhibitor, Patel concludes.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD